



1646

Patent  
030639.0043.UTL2

#7/RW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Beeley et al.

Serial No.: 09/554,533

Filed: November 13, 1998

For: NOVEL EXENDIN AGONIST  
COMPOUNDS

Group Art Unit: To be assigned

Examiner: To be assigned

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The following information is brought to the attention of the Examiner. The information is listed on the attached form PTO/SB/08A and copies are enclosed for the convenience of the Examiner. Applicant respectfully requests that an initialed copy of the PTO/SB/08A be returned with the next Communication.

This Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b)(3) before the mailing of a first Office Action on the merits, whereby no petition or fee is required. However, if counsel for Applicants is in error in this regard, the Commissioner is requested to consider this a petition and charge any required petition fee to counsel's Deposit Account No. 50-1273.

Respectfully submitted,

Dated: 12-20-02

By: Lisa M. Griffith  
Lisa M. Griffith  
Reg. No. 41,185

BROBECK, PHLEGER & HARRISON LLP  
12390 El Camino Real  
San Diego, CA 92130  
Direct Telephone Number: (858) 720-2584  
Facsimile Number: (858) 720-2555

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

12/23/02  
Date of Deposit

Laura V. Largey  
Laura V. Largey



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	09/554,533
Filing Date	November 13, 1998
First Named Inventor	Beeley, Nigel Robert Arnold
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	030639.0043.UTL2

Sheet	1	of	5
-------	---	----	---

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	5,118,666		Habener	06/02/1992	
	AB	5,120,712		Habener	06/09/1992	
	AC	5,424,286		Eng	06/13/1995	
	AD	5,512,549		Chen	04/30/1996	
	AE	5,545,618		Buckley	08/13/1995	
	AF	5,574,008		Johnson	11/12/1996	
	AG	5,686,511		Bobo	11/11/1997	
	AH	6,191,102	B1	DiMarchi et al.	02/20/2001	

TECH CENTER 1600/2900

JAN 02 2003

RECEIVED

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AI	WO	9011296		Habener	10/04/1990		
	AJ	WO	9111457		Buckley	08/08/1991		
	AK	WO	9318786		Efendic	09/30/1993		
	AL	WO	9325579		Andrews	12/23/1993		
	AM	WO	9805351	A1	Amylin Pharmaceuticals, Inc.	02/12/1998		
	AN	WO	9819698	A1	Eli Lilly and Company	05/14/1998		
	AO	WO	9830231	A1	Amylin Pharmaceuticals, Inc.	07/16/1998		
	AP	WO	9907404	A1	Amylin Pharmaceuticals, Inc.	02/18/1999		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

C:\NrPortb\SDILIB\SL470757\_1.DOC



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/554,533
				Filing Date	November 13, 1998
				First Named Inventor	Beeley, Nigel Robert Arnold
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	5	Attorney Docket Number	030639.0043.UTL2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AQ	ADELHORST, K., et al., "Structure-activity Studies of Glucagon-like Peptide-1 (GLP-1)," <u>J. Biol. Chem.</u> , 269(9):6275-8 (1994)	TECH CENTER 1600/2900
	AR	BARTLETT, et al., "Inhibition of Chymotrypsin by Phosphonate and Phosphoramidate Peptide Analogs," <u>Bioorg. Chem.</u> , 14:356-377 (1986)	
	AS	BHAVSAR, "Inhibition of Gastric Emptying and of Food Intake Appear to Be Independently Controlled in Rodents," <u>Soc. Neurosci. Abst.</u> , 21:460 (188.8)(1995)	
	AT	COHEN, et al., <u>The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis</u> , pp. 11-52, Millipore Corporation (1989)	
	AU	D'ALESSIO, et al., "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons," <u>J. Clin. Invest.</u> , 97:133-38 (1996)	
	AV	EISSELE, et al., "Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide," <u>Life Sci.</u> , 55:629-34 (1994)	
	AW	ENG, et al., "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom," <u>J. Biol. Chem.</u> , 267:7402-05 (1992)	
	AX	ENG, et al., "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <u>J. Biol. Chem.</u> , 265:20259-62 (1990)	
	AY	FEHMANN, et al., "Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39)," <u>Peptides</u> , 15(3):453-6 (1994)	
	AZ	FERGUSON, et al., "Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures," <u>Annu. Rev. Biochem.</u> , 57:285-320 (1988)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

C:\NrPort\B\SDILIB\SL\470757\_1.DOC

RECEIVED  
JAN 02 2003



Please place a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/554,533
				Filing Date	November 13, 1998
				First Named Inventor	Beeley, Nigel Robert Arnold
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	5	Attorney Docket Number	030639.0043.UTL2

BA	GOKE, et al., "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting $\beta$ -Cells," <i>J. Biol. Chem.</i> , 268:19650-55 (1993)	
BB	GOLDSTONE, et al., "Leptin Interacts with Glucagon-like Peptide-1 Neurons to Reduce Food Intake and Body Weight in Rodents," <i>FEBS Letters</i> , 415:134-138 (1997)	
BC	HALAAS, J.L., et al., "Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene," <i>Science</i> , 269:543-546 (1995)	
BD	KODAMA, J., et al., "Effect of Captopril on Glucose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow," <i>Diabetes Care</i> , 13(11):1109-1111 (1990)	
BE	KOLLIGS, et al., "Reduction of the Incretin Effect in Rats by the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9-39) Amide," <i>Diabetes</i> , 44:16-19 (1995)	
BF	LEIBEL, R.L., et al., "Changes in Energy Expenditure Resulting from Altered Body Weight," <i>New England Journal of Medicine</i> , 332(10):621-628 (1995)	
BG	LITHELL, et al., "Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters," <i>J. Cardiovasc. Pharmacol.</i> , 15 (Supp 5):S46-S52 (1990)	
BH	MALHOTRA, et al., "Exendin-4, a New Peptide from <i>Heloderma suspectum</i> Venom, Potentiates Cholecystokinin-induced Amylase Release from Rat Pancreatic Acini," <i>Regulatory Peptides</i> , 41:149-56 (1992)	
BI	MONTROSE-RAFIZADEH, et al., "Structure-function Analysis of Exendin-4 / GLP-1 Analogs," <i>Diabetes</i> , 45 (Suppl. 2):152A (1996)	
BJ	NAVARRO, M. et al., "Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake," <i>Journal of Neurochemistry</i> , 67:1982-1991 (1996)	
BK	O'HALLORAN, et al., "Glucagon-like Peptide-1 (7-36)-NH <sub>2</sub> : a Physiological	

TECH CENTER 1609/2900

JAN 02 2003

RECEIVED

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/554,533
				Filing Date	November 13, 1998
				First Named Inventor	Beeley, Nigel Robert Arnold
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	4	of	5	Attorney Docket Number	030639.0043.UTL2

		Inhibitor of Gastric Acid Secretion in Man," <u>J. Endocrinol.</u> , 126(1):169-73 (1990)	
	BL	ØRSKOV, et al., "Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable," <u>Diabetes</u> , 42:658-61 (1993)	
	BM	PELLEYMOUNTER, et al., "Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice," <u>Science</u> , 269:540-543 (1995)	
	BN	RAUFMAN, et al., "Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas," <u>J. Biol. Chem.</u> , 267:21432-37 (1992)	
	BO	RAUFMAN, et al., "Exendin-3, a Novel Peptide from <i>Heloderma horridum</i> Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas," <u>J. Biol. Chem.</u> , 266:2897-902 (1991)	
	BP	SCHEPP, et al., "Exendin-4 and exendin-(9-39)NH <sub>2</sub> : Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH <sub>2</sub> ," <u>Eur. J. Pharm.</u> , 269:183-91 (1994)	
	BQ	SCHJOLDAGER, et al., "GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans," <u>Dig. Dis. Sci.</u> , 34 (5):703-8 (1989)	
	BR	SINGH, et al., "Use of <sup>125</sup> I-[Y <sup>39</sup> ]Exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief Cells from Guinea Pig," <u>Regul. Pept.</u> , 53:47-59 (1994)	
	BS	THORENS, "Expression Cloning of the Pancreatic B Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1," <u>Proc. Natl. Acad. Sci. USA</u> , 89:8641-45 (1992)	
	BT	THORENS, et al., "Cloning and Functional Expression of the Human Islet GLP-1 Receptor," <u>Diabetes</u> , 42 (11):1678-82 (1993)	
	BU	TURTON, et al., "A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding," <u>Nature</u> , 379:69-72 (1996)	
	BV	VEALE, P.R., et al., "The Presence of Islet Amyloid Polypeptide/Calcitonin Gen-Related Peptide/Salmon Calcitonin Binding Sites in the Rat Nucleus	

TECH CENTER 1600/2900

RECEIVED  
JAN 02 2003

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/554,533
				Filing Date	November 13, 1998
				First Named Inventor	Beeley, Nigel Robert Arnold
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	5	of	5	Attorney Docket Number	030639.0043.UTL2

		Accumbens," <u>European Journal of Pharmacology</u> , 262:133-141 (1994)	
	BW	WANG, et al., "Glucagon-like Peptide-1 Is a Physiological Incretin in Rat," <u>J. Clin. Invest.</u> , 95:417-21 (1995)	
	BX	WATSON, N., et al., "Effects of Captopril on Glucose Tolerance in Elderly Patients with Congestive Cardiac Failure," <u>Current Medical Research and Opinion</u> , 12(6):374-378 (1991)	
	BW	WETTERGREN, et al., "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," <u>Dig. Dis. Sci.</u> , 38(4):665-73 (1993)	
	BZ	WILLMS, et al., "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients," <u>J. Clin. Endocrinol. Metab.</u> , 81(1):327-32 (1996)	
	CAZ	YOUNG, et al., <u>Program and Abstracts, 10<sup>th</sup> International Congress of Endocrinology</u> June 12-15, 1996, San Francisco, p. 419 (P2-58)	

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

C:\NrPortb\SDILIB\SL\470757\_1.DOC